In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes.

@article{Hadri2004InVS,
  title={In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes.},
  author={Khadija El Hadri and Martine Glorian and Christelle Monsemp{\`e}s and M N Dieudonne and Ren{\'e} Pecquery and Yves Giudicelli and Marise Andr{\'e}ani and Isabelle Dugail and Bruno F{\`e}ve},
  journal={The Journal of biological chemistry},
  year={2004},
  volume={279 15},
  pages={15130-41}
}
A serious metabolic syndrome combining insulin-resistance, dyslipidemia, central adiposity, and peripheral lipoatrophy has arisen in HIV-infected patients receiving highly active antiretroviral therapy. The aim of this work was to examine the effects of the nonnucleoside reverse transcriptase inhibitor (NNRTI) efavirenz on adipocyte differentiation and metabolism. When induced to differentiate in the presence of efavirenz (5-50 microm), 3T3-F442A preadipocytes failed to accumulate cytoplasmic… CONTINUE READING